Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria

NCT01860222 is registered in ClinicalTrials.gov with Eastern Hepatobiliary Surgery Hospital as lead sponsor.

NCT NCT01860222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01860222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 31, 2011
Completion date
December 31, 2016
Enrollment
160 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma with csph